BioMarin Pharmaceutical Inc.
105 Digital Drive
About BioMarin Pharmaceutical Inc.
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.
BioMarin offers a friendly, fast-paced, collegial environment where success is measured by both the individual and collective efforts of hundreds of talented scientists, business professionals, technical specialists and experts in a variety of fields from sales and marketing, to finance, to manufacturing, to clinical and regulatory operations.
BioMarin is growing rapidly to support the development and global commercialization of breakthrough drugs to treat rare genetic diseases. The company’s product portfolio comprises seven approved products and multiple clinical and pre-clinical product candidates.
You can make it happen at BioMarin, where the unique combination of big-company success in a small-company environment provides unparalleled opportunity for individual contributions and growth.
What makes working here unique? At BioMarin, we feel the intense tie between the work we do and the life-changing results it delivers. Our focus on rare disease gives us the rare opportunity to truly impact lives.
603 articles with BioMarin Pharmaceutical Inc.
BioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CA
BioMarin Pharmaceutical Inc. announced that Henry Fuchs, M.D., President, Worldwide Research & Development, will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 at 8:40am PT/11:40am ET in Rancho Palos Verdes, California.
BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome
BioMarin Pharmaceutical Inc. announced that Vimizim® has been approved by the National Medical Products Administration for the treatment of patients with mucopolysaccharidosis type IVA, also known as Morquio A syndrome.
Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.
BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
BioMarin Pharmaceutical Inc. announced an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A.
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
BioMarin Pharmaceutical Inc. announced that its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A achieved pre-specified clinical criteria for regulatory review in the U.S. and Europe.
“Reaching this pre-specified clinical endpoint is an important milestone that brings us one step closer to a potential regulatory submission in both the U.S. and Europe for valoctocogene roxaparvovec to treat adults with severe hemophilia A,” stated Hank Fuchs, president of Worldwide Research and...
BioMarin to Host Conference Call Tuesday, May 28, 2019 to Provide a Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update
BioMarin Pharmaceutical Inc., announced that management will host a conference call and webcast on Tuesday, May 28 at 8:00am ET to discuss program updates.
BioMarin to Participate in 2019 RBC Capital Markets Global Healthcare Conference on May 21 in New York City
BioMarin Pharmaceutical Inc. announced that Robert Baffi, Ph.D., Executive Vice President, Technical Operations, will participate in a gene therapy manufacturing focused fireside chat at the RBC Capital Markets Global Healthcare Conference on May 21 at 8:00am ET in New York City.
BioMarin to Participate in Bank of America Merrill Lynch Health Care Conference on May 15 in Las Vegas
BioMarin Pharmaceutical Inc., announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care Conference on May 15 at 11:20am PT/2:20pm ET in Las Vegas.
European Commission Approves Palynziq® (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 Years or Older
First Enzyme Substitution Therapy Approved in Europe to Treat the Underlying Cause of PKU in Patients Aged 16 Years or Older at Doses up to 60 mg
BioMarin Pharmaceutical Inc. announced financial results for the first quarter ended March 31, 2019.
Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.
Company Ranks 1st Among Midsize Employers in 'Drugs & Biotechnology' Industry
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a lo...
The San Francisco Business Times came out with a list of 64 major Bay Area employers and their median pay, which they then compared to their chief executives’ annual compensation.
4/5/2019In January 2019, the U.S. Food and Drug Administration (FDA) updated a 2015 draft guidance on rare diseases.
BioMarin to Host First Quarter 2019 Financial Results Conference Call and Webcast on Thursday, April 25 at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 25, at 4:30 p.m. ET to discuss first quarter 2019 financial results and provide a general business update.
BioMarin to Participate in Cowen and Company 39th Annual Health Care Conference on March 12 in Boston
A replay will be archived on the site for at least one week following each event.
BioMarin Receives Positive CHMP Opinion in Europe for Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU) Aged 16 and Older
In Phase 3 Trial, Palynziq Substantially Reduced Blood Phenylalanine Levels, While Increasing Dietary Protein; Data Suggestive of Beneficial Effects on Inattention and Mood Symptoms
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
--Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure-- [26-February-2019] SAN FRANCISCO , Feb. 26, 2019 /PRNewswire/ -- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions,